2023 Fiscal Year Annual Research Report
miRNA-9 delivery using lactosome, a newly-developed drug delivery system, in the treatment of rheumatoid arthritis
| Project/Area Number |
22K16341
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
LEE WENSHI 東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (30883590)
|
|---|
| Project Period (FY) |
2022-04-01 – 2024-03-31
|
| Keywords | Lactosome / miRNA-9 / RasGRP4 / Rheumatoid Arthritis |
|---|
| Outline of Annual Research Achievements |
Lactosome-miR-9 was injected intravenously into a collagen-induced arthritis mouse model, with lactosome-control siRNA serving as the control group. The mean arthritic score was relatively lower in the miR-9 group compared to the control group. Histological assessments of the joints in the lactosome-miR-9 group showed reduced inflammation. STIA mice was used to induce arthritis and repeated the experiments to confirm the efficacy of lactosome-miR-9 in a different arthritis model.
We investigated the potential of targeting RasGRP4 using lactosome:
RasGRP4 deficiency attenuated both K/BxN STIA and AIA without suppressing adaptive immune responses.
|
